Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
Sucampo Pharmaceuticals, Inc. (SCMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/13/2018 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Sucampo Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Sucampo Pharmaceuticals, Inc",
"Supplemental Indenture, between Sucampo Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee"
01/02/2018 8-K Other Events
Docs: "FORM 8-K"
12/26/2017 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "FORM 8-K",
"Agreement and Plan of Merger, by and among Sucampo Pharmaceuticals, Inc., Mallinckrodt plc and Sun Acquisition Co",
"Mallinckrodt to Acquire Sucampo Pharmaceuticals for Approximately $1.2 Billion — Immediately accretive transaction includes development and commercial assets including AMITIZA ® , a leading product in branded constipation market — — Mallinckrodt expects accretion to 2018 adjusted diluted earnings per share of at least $0.30; and at least double that in 2019, assuming expected first quarter 2018 close — — Mallinckrodt to commence cash tender offer for $18.00 per share, with support from key Sucampo shareholders"
11/16/2017 8-K Investor presentation
11/01/2017 8-K Quarterly results
09/26/2017 8-K Quarterly results
09/20/2017 8-K Quarterly results
09/08/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
07/19/2017 8-K Form 8-K - Current report:
06/06/2017 8-K Form 8-K - Current report
05/03/2017 8-K Form 8-K - Current report
04/03/2017 8-K Form 8-K - Current report
03/13/2017 8-K Form 8-K - Current report
03/08/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
12/27/2016 8-K Form 8-K - Current report
12/19/2016 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/26/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
07/29/2016 8-K Form 8-K - Current report
07/12/2016 8-K Form 8-K - Current report
06/08/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
03/08/2016 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: ",1",
"The corporate update presentation slides"
02/11/2016 8-K Form 8-K - Current report
01/14/2016 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis"
01/11/2016 8-K Investor presentation
Docs: "Presentation titled “Sucampo Pharmaceuticals, Inc. Corporate Update” dated January 11-13, 2016"
01/07/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Sucampo Provides Update to 2015 and Confirms 2016 Financial Guidance Post Closing of R-Tech Ueno Acquisition ROCKVILLE, Md., Jan. 07, 2016 -- Sucampo Pharmaceuticals, Inc. , a global biopharmaceutical company, today provided additional detail regarding its previously announced guidance for 2015 and 2016, to include expected non-cash purchase accounting adjustments and expenses related to the R-Tech Ueno acquisition that closed in the fourth quarter of 2015. For the full year ended December 31, 2015, Sucampo expects to achieve adjusted net income in the range of $30.0 million to $35.0 million, adjusted EPS of $0.65 to $0.75 per diluted share, and adjusted EBITDA of $55.0 million to $60.0 million. Adjusted net income includes approximately $5.3 million in interest and debt issuance expense a..."
12/15/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Sucampo CEO Peter Greenleaf Appointed Chairman of the Board of Directors"
12/02/2015 8-K Investor presentation
Docs: "Presentation titled “Piper Jaffray 27th Annual Healthcare Conference”"
11/04/2015 8-K Quarterly results
Docs: "Sucampo Reports Third Quarter 2015 Financial Results and Provides Corporate Update",
"The corporate update presentation slides"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy